ストックスクリーナーアプリを入手
14.20
2.23%
0.31
アフターアワーズ：
14.21
0.01
+0.07%
前日終値:
$13.89
開ける：
$14.02
24時間の取引高:
76,204
Relative Volume:
2.18
時価総額：
$4.81B
収益：
$417.75M
当期純損益:
$32.27M
株価収益率:
145.64
EPS:
0.0975
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-12.51%
1か月 パフォーマンス:
-11.19%
6か月 パフォーマンス:
-22.15%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$13.88
$14.24
1週間の範囲:
$13.87
$16.94
52週間の値動き範囲:
$13.61
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
14.20 | 4.65B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-03 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-05 | 開始されました | Wedbush | Outperform |
| 2024-11-15 | 開始されました | UBS | Buy |
Telix Pharmaceuticals Ltd Adr (TLX) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Telix Pharma slides 10% on SEC probe into cancer treatment - Investing.com
Telix Earnings Report: $204M Revenue Crushes Estimates as New Drug Launch Boosts Growth - Stock Titan
Medicare Grants Crucial Reimbursement Code for Telix's Next-Gen Prostate Cancer Imaging Agent - Stock Titan
H.C. Wainwright initiates Telix Pharmaceuticals stock with Buy rating on radiotherapy portfolio - Investing.com
FDA Approval: Illuccix Expansion Could Add 20,000 Annual Prostate Cancer Scans - Stock Titan
Revolutionary Dual-Isotope Cancer Imaging: Telix Unveils AlFluor Platform with Phase 3 Trial Success - Stock Titan
Revolutionary PSMA-PET Imaging Agent Gozellix Transforms Prostate Cancer Detection Across United States - Stock Titan
Leading Cancer Experts Reveal Future of Radiopharmaceuticals at Telix NYC Investor Day - Stock Titan
5 of the best ASX 200 shares to buy in June - The Motley Fool Australia
Telix Leaders Reveal Next-Gen Radiopharmaceutical Pipeline at Exclusive NYC Investor Day - Stock Titan
Radiopharmaceuticals Market Products and Applications Report 2025 | SPECT Radiopharmaceuticals Lead Diagnostic Market with 67% Share - GlobeNewswire Inc.
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - Stock Titan
Major Breakthrough: France Grants Approval for Advanced Prostate Cancer Detection Technology - Stock Titan
Telix Delivers Record $186M Q1 Revenue as New FDA-Approved Cancer Imaging Agent Bolsters Portfolio - Stock Titan
Breakthrough Brain Cancer Treatment Doubles Survival Time: Phase 2 Results Revealed - Stock Titan
Telix's Groundbreaking Prostate Cancer Imaging Tech Secures Nationwide Distribution Network - Stock Titan
Telix Pharmaceuticals appoints new CTO - Investing.com
Major Board Addition: Ex-GSK and Sanofi Leader Joins Telix Pharmaceuticals - Stock Titan
Revolutionary Cancer Diagnostic Begins Human Trials: First Patient Receives Novel Sarcoma Imaging Agent - Stock Titan
FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer - StockTitan
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix® - The Capital Club
Paladin Energy Ltd (ASX:PDN) Suspends Operations at Langer Heinrich Mine - The Capital Club
Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market - StockTitan
Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production - StockTitan
Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan
特斯拉將收購德國Manz部分資產 增強德國自動化實力 - Yahoo 財經
〈強茂展望〉擴大海外布局 越南廠最快2026年量產 - Yahoo 財經
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
特朗普：或將DOGE所節省開支的20%歸還予美國納稅人 - Yahoo 財經
港股美國預託證券與本港收市比較個別發展 - Yahoo 財經
據報匯控最快下周啟動投行部門新一輪裁員 由亞洲開始 - Yahoo 財經
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results - StockTitan
Major Breakthrough: Revolutionary Prostate Cancer Detection Tool Gets UK Green Light - StockTitan
《業績》可口可樂(KO.US)上季盈收勝預期 受惠價格上升9% - Yahoo 財經
分析國產人工智能 DeepSeek 的優與劣及其競爭力 - Yahoo 財經
Telix Pharmaceuticals acquires ImaginAb assets and technology - Investing.com
Telix Pharmaceuticals Acquires RLS USA in Major $230M Radiopharmacy Network Deal - Stock Titan
ImaginAb Sells Therapeutic Pipeline to Telix Pharmaceuticals, Focuses on CD8 ImmunoPET Development - Stock Titan
Telix Pharmaceuticals Secures European Approval for Breakthrough Prostate Cancer Imaging Agent Illuccix - Stock Titan
Telix Pharmaceuticals Hits Record $517M Revenue, Up 55% as Cancer Imaging Portfolio Expands - Stock Titan
Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal - StockTitan
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
勞力士據報因材料及勞動力成本上漲 加價最多8% - Yahoo 財經
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
本田及日產確認研究合併可能性 日產股價急彈24% - Yahoo 財經
無人機技術公司Red Cat(RCAT.US)股價漲18% 將與Palantir(PLTR.US)合作 - Yahoo 財經
信德(00242.HK)附屬向合資公司提供最多1.08億元額外股東貸款 - Yahoo 財經
Telix Pharmaceuticals Ltd Adr (TLX) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):